Cargando…
Double-Blind, Randomized, Placebo-Controlled Study on hzVSF-v13, a Novel Anti-Vimentin Monoclonal Antibody Drug as Add-on Standard of Care in the Management of Patients with Moderate to Severe COVID-19
Humanized Virus Suppressing Factor-variant 13 (hzVSF-v13), a monoclonal IgG4 antibody against vimentin, was investigated in moderate to severe COVID-19 pneumonia through a Phase II study. Patients were randomized to two different IV doses of the test drug or saline with standard of care. Overall, 64...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181020/ https://www.ncbi.nlm.nih.gov/pubmed/35683351 http://dx.doi.org/10.3390/jcm11112961 |
_version_ | 1784723664324788224 |
---|---|
author | Prasenohadi, Prasenohadi Burhan, Erlina Dhunny, Sri Suharno, Wahyuningsih Wabnitz, Paul Kim, Yoon-Won Petrosillo, Nicola |
author_facet | Prasenohadi, Prasenohadi Burhan, Erlina Dhunny, Sri Suharno, Wahyuningsih Wabnitz, Paul Kim, Yoon-Won Petrosillo, Nicola |
author_sort | Prasenohadi, Prasenohadi |
collection | PubMed |
description | Humanized Virus Suppressing Factor-variant 13 (hzVSF-v13), a monoclonal IgG4 antibody against vimentin, was investigated in moderate to severe COVID-19 pneumonia through a Phase II study. Patients were randomized to two different IV doses of the test drug or saline with standard of care. Overall, 64 patients were recruited, and 62 entered the efficacy assessment in the full analysis set. Primary endpoint: The clinical failure rate at day 28 was 15.8% for placebo, 9.1% for low-dose hzVSF-v13 and 9.5% for high-dose hzVSF-v13 (not significant). A trend toward better efficacy was shown in several secondary endpoints, with statistical significance between low-dose hzVSF-v13 and placebo in terms of the rate of improved patients on the ordinal scale for clinical improvement (OSCI): 90.0% vs. 52.63% (p = 0.0116). In the severe stratum, the results of low-dose hzVSF-v13 vs. placebo were 90.0% and 22.2% for OSCI (p = 0.0092), 9 days and 14 days for time to discontinuation of oxygen therapy (p = 0.0308), 10 days and 15 days for both time to clinical improvement (TTCI) and time to recovery (TTR) and p = 0.0446 for both TTCI and TTR. Change from baseline of NEWS2 score at day 28 was −3.4 vs. + 0.4 (p = 0.0441). The results propose hzVSF-v13 as a candidate in the treatment of severe COVID-19. |
format | Online Article Text |
id | pubmed-9181020 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91810202022-06-10 Double-Blind, Randomized, Placebo-Controlled Study on hzVSF-v13, a Novel Anti-Vimentin Monoclonal Antibody Drug as Add-on Standard of Care in the Management of Patients with Moderate to Severe COVID-19 Prasenohadi, Prasenohadi Burhan, Erlina Dhunny, Sri Suharno, Wahyuningsih Wabnitz, Paul Kim, Yoon-Won Petrosillo, Nicola J Clin Med Article Humanized Virus Suppressing Factor-variant 13 (hzVSF-v13), a monoclonal IgG4 antibody against vimentin, was investigated in moderate to severe COVID-19 pneumonia through a Phase II study. Patients were randomized to two different IV doses of the test drug or saline with standard of care. Overall, 64 patients were recruited, and 62 entered the efficacy assessment in the full analysis set. Primary endpoint: The clinical failure rate at day 28 was 15.8% for placebo, 9.1% for low-dose hzVSF-v13 and 9.5% for high-dose hzVSF-v13 (not significant). A trend toward better efficacy was shown in several secondary endpoints, with statistical significance between low-dose hzVSF-v13 and placebo in terms of the rate of improved patients on the ordinal scale for clinical improvement (OSCI): 90.0% vs. 52.63% (p = 0.0116). In the severe stratum, the results of low-dose hzVSF-v13 vs. placebo were 90.0% and 22.2% for OSCI (p = 0.0092), 9 days and 14 days for time to discontinuation of oxygen therapy (p = 0.0308), 10 days and 15 days for both time to clinical improvement (TTCI) and time to recovery (TTR) and p = 0.0446 for both TTCI and TTR. Change from baseline of NEWS2 score at day 28 was −3.4 vs. + 0.4 (p = 0.0441). The results propose hzVSF-v13 as a candidate in the treatment of severe COVID-19. MDPI 2022-05-24 /pmc/articles/PMC9181020/ /pubmed/35683351 http://dx.doi.org/10.3390/jcm11112961 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Prasenohadi, Prasenohadi Burhan, Erlina Dhunny, Sri Suharno, Wahyuningsih Wabnitz, Paul Kim, Yoon-Won Petrosillo, Nicola Double-Blind, Randomized, Placebo-Controlled Study on hzVSF-v13, a Novel Anti-Vimentin Monoclonal Antibody Drug as Add-on Standard of Care in the Management of Patients with Moderate to Severe COVID-19 |
title | Double-Blind, Randomized, Placebo-Controlled Study on hzVSF-v13, a Novel Anti-Vimentin Monoclonal Antibody Drug as Add-on Standard of Care in the Management of Patients with Moderate to Severe COVID-19 |
title_full | Double-Blind, Randomized, Placebo-Controlled Study on hzVSF-v13, a Novel Anti-Vimentin Monoclonal Antibody Drug as Add-on Standard of Care in the Management of Patients with Moderate to Severe COVID-19 |
title_fullStr | Double-Blind, Randomized, Placebo-Controlled Study on hzVSF-v13, a Novel Anti-Vimentin Monoclonal Antibody Drug as Add-on Standard of Care in the Management of Patients with Moderate to Severe COVID-19 |
title_full_unstemmed | Double-Blind, Randomized, Placebo-Controlled Study on hzVSF-v13, a Novel Anti-Vimentin Monoclonal Antibody Drug as Add-on Standard of Care in the Management of Patients with Moderate to Severe COVID-19 |
title_short | Double-Blind, Randomized, Placebo-Controlled Study on hzVSF-v13, a Novel Anti-Vimentin Monoclonal Antibody Drug as Add-on Standard of Care in the Management of Patients with Moderate to Severe COVID-19 |
title_sort | double-blind, randomized, placebo-controlled study on hzvsf-v13, a novel anti-vimentin monoclonal antibody drug as add-on standard of care in the management of patients with moderate to severe covid-19 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181020/ https://www.ncbi.nlm.nih.gov/pubmed/35683351 http://dx.doi.org/10.3390/jcm11112961 |
work_keys_str_mv | AT prasenohadiprasenohadi doubleblindrandomizedplacebocontrolledstudyonhzvsfv13anovelantivimentinmonoclonalantibodydrugasaddonstandardofcareinthemanagementofpatientswithmoderatetoseverecovid19 AT burhanerlina doubleblindrandomizedplacebocontrolledstudyonhzvsfv13anovelantivimentinmonoclonalantibodydrugasaddonstandardofcareinthemanagementofpatientswithmoderatetoseverecovid19 AT dhunnysri doubleblindrandomizedplacebocontrolledstudyonhzvsfv13anovelantivimentinmonoclonalantibodydrugasaddonstandardofcareinthemanagementofpatientswithmoderatetoseverecovid19 AT suharnowahyuningsih doubleblindrandomizedplacebocontrolledstudyonhzvsfv13anovelantivimentinmonoclonalantibodydrugasaddonstandardofcareinthemanagementofpatientswithmoderatetoseverecovid19 AT wabnitzpaul doubleblindrandomizedplacebocontrolledstudyonhzvsfv13anovelantivimentinmonoclonalantibodydrugasaddonstandardofcareinthemanagementofpatientswithmoderatetoseverecovid19 AT kimyoonwon doubleblindrandomizedplacebocontrolledstudyonhzvsfv13anovelantivimentinmonoclonalantibodydrugasaddonstandardofcareinthemanagementofpatientswithmoderatetoseverecovid19 AT petrosillonicola doubleblindrandomizedplacebocontrolledstudyonhzvsfv13anovelantivimentinmonoclonalantibodydrugasaddonstandardofcareinthemanagementofpatientswithmoderatetoseverecovid19 |